BurstDR Spinal Cord Stimulation Versus Sham in Established Responders
- Sponsor
- Umeå University
- Study ID
- NCT07779733
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Chronic Pain
Eligibility Criteria
- Sex
- ALL
- Age
- N/A - N/A
- Healthy Volunteers
- Not accepted
Interventions
- BurstDR Spinal Cord Stimulation — DEVICEActive BurstDR spinal cord stimulation is delivered for 7 consecutive days using each participant's established clinically effective stimulation settings. Electrode configuration, pulse pattern, pulse width, frequency structure, and amplitude are maintained according to the participant's established therapeutic program, with any adjustment required to maintain imperceptible stimulation completed before the randomized treatment periods.
- Sham Spinal Cord Stimulation — DEVICEDuring sham stimulation, the implanted spinal cord stimulation system remains in place but stimulation output is switched off for 7 consecutive days. The participant-facing programmer is locked and visible device information that could reveal treatment allocation is masked. Study contacts, diary assessments, and follow-up procedures are otherwise equivalent to those during active stimulation.
Study Details
This study aims to determine whether ongoing BurstDR spinal cord stimulation (SCS) provides pain relief beyond sham stimulation in patients with chronic pain who are established responders to BurstDR therapy. Participants already implanted with an SCS system and experiencing stable clinical benefit from BurstDR will undergo both active stimulation and sham stimulation in a randomized, double-blind crossover design. Each participant will therefore serve as their own control. The primary question is whether pain intensity is lower during active BurstDR stimulation compared with sham stimulation. The study will also evaluate treatment satisfaction, patient-reported changes in sleep, mood, daily activity and social activity, the effectiveness of blinding, and short-term safety and tolerability.
Key Dates
- First listed
- Aug 21, 2026
- Start date
- Sep 30, 2026
- Status verified
- Aug 2026
- Primary completion
- Dec 31, 2026
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 28 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- CROSSOVER
- Primary purpose
- TREATMENT
Arms
- Experimental: equence 1: Active BurstDR → ShamFollowing a 1-day baseline observation under established active BurstDR settings, participants undergo a 4-day washout period with stimulation switched off. They then receive 7 days of active BurstDR spinal cord stimulation using their established clinically effective settings. After a second 4-day washout period with stimulation switched off, participants receive 7 days of sham stimulation, during which stimulation output remains switched off.
- Experimental: Sequence 2: Sham → Active BurstDRFollowing a 1-day baseline observation under established active BurstDR settings, participants undergo a 4-day washout period with stimulation switched off. They then receive 7 days of sham stimulation, during which stimulation output remains switched off. After a second 4-day washout period with stimulation switched off, participants receive 7 days of active BurstDR spinal cord stimulation using their established clinically effective settings.
Primary Outcome Measure
Within-Participant Difference in Period-Level Median Numeric Rating Scale Pain Intensity Between Active BurstDR and Sham [ Time Frame: During each 7-day randomized treatment period (Days 5-11 and Days 16-22 after baseline) ]
Central Contacts
- Pedram Tabatabaei, MD, PhD+46-70-7603239
Related Studies
- Patient Retrospective Outcomes (PRO)Recruiting · Boston Scientific Corporation · Lake Havasu City, Arizona
- QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory TestingRecruiting · Anna Evans Phillips · Baltimore, Maryland
- Long-Term Real-World Outcomes Study on Patients Implanted With a NeurostimulatorRecruiting · Abbott Medical Devices · Phoenix, Arizona
- PAIN: A Project Assessing the Impact of a Novel Cannabinoid ProductPHASE2 · Recruiting · Staci Gruber, Ph.D. · Belmont, Massachusetts